drugset / Trial / NCT00003236

Chemotherapy in Treating Women With Previously Treated Metastatic Breast Cancer

NCT00003236 ↗

RandomizedTreatment

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Randomized phase II trial to compare the effectiveness of ISIS 5132 with ISIS 3521 in treating women who have metastatic breast cancer that has not responded to previous therapy.

Timeline

Start
1998-07-13
Primary completion
2002-06
Completion
—

Publications

  • Results Gradishar WJ, O'Neill A, Cobleigh M, et al.: A phase II trial with antisense oligonucleotide ISIS 3521/Cgp 64128a in patients (Pts) with metastatic breast cancer (MBC): ECOG trial 3197. [Abstract] Proceedings of the American Society of Clinical Oncology 20: A-171, 2001.

Drugs

EvaluationDrugModalityDoseRoute
Subject ISIS 3521 Antisense oligonucleotide — Intravenous
Subject ISIS 5132 Antisense oligonucleotide — Intravenous

Indications